Commonly used bowel preparations have significant and different effects upon cell proliferation in the colon: a pilot study
© Croucher et al; licensee BioMed Central Ltd. 2008
Received: 19 May 2008
Accepted: 14 November 2008
Published: 14 November 2008
Markers of crypt cell proliferation are frequently employed in studies of the impact of genetic and exogenous factors on human colonic physiology. Human studies often rely on the assessment of tissue acquired at endoscopy. Modulation of cell proliferation by bowel preparation with oral laxatives may confound the findings of such studies, but there is little data on the impact of commonly used bowel preparations on markers of cell proliferation.
Crypt length, crypt cellularity and crypt cell proliferation were assessed in biopsies acquired after preparation with either Klean-Prep or Picolax. Crypt cell proliferation was assessed by whole-mount mitotic figure count, and by two different immunohistochemical (IHC) labelling methods (Ki-67 and pHH3). Subsequent biopsies were obtained from the same patients without bowel preparation and similarly assessed. Parameters were compared between groups using analysis of variance and paired t-tests.
There were significant differences in labelling indices (LI) between biopsies taken after Klean-prep and those taken after Picolax preparation, for both Ki67 (p = 0.019) and pHH3 (p = 0.017). A similar trend was seen for whole-mount mitotic figure counts. Suppression or elevation of proliferation parameters by bowel preparation may mask any effect due to an intervention or disease.
Commonly used bowel preparations may have significant and different effects on crypt cell proliferation. This should be taken into account when designing studies and when considering the findings of existing studies.
Oral laxatives are routinely used to cleanse the colon prior to colonoscopy, to permit clear visualisation of the colonic mucosa and minimise the risk of infection. Hyperosmotic preparations such as sodium phosphate (NaP) and Picolax® actively draw water into the bowel lumen, increasing stool bulk and stimulating gut motility. The effect is lavage with rapid transit and evacuation of bowel contents. The fluid and electrolyte imbalance that may occur with preparations of this type precludes their use in patients with renal or congestive heart failure, but they are otherwise well tolerated. Klean-Prep® is principally a lavage solution with some osmotic activity, the large ingestion volume being retained within the colon by polyethelene glycol (PEG), itself relatively inert and poorly absorbed. Although the risk of significant fluid or electrolytes shifts is reduced with PEG based preparations, the large ingestion volume can be associated with poor patient compliance.
Ideally, a bowel preparation agent should have minimal impact on the colonic mucosa. However, endoscopic and histological abnormalities have been reported, particularly with NaP, and include inflammation, haemorrhage, focal active colitis (FAC), erosion of the surface epithelium and apthoid ulceration [5–7]. One study reported apthoid lesions in 24.5% of patients prepared with NaP, compared to only 2.3% of patients prepared with PEG and concluded that NaP should not be used to prepare patients with suspected inflammatory bowel disease. Another study attributing FAC and aphthoid ulcers to NaP found no lesions in a subset of patients subsequently re-examined without preparation. Sodium picosulfate, the active constituent of Picolax, has been shown to increase the expression of acidic mucin and cytokeratin AE1 in rat colonocytes. The effects of PEG on the morphology of the colonic mucosa are less clear. No significant changes were attributed to PEG in two studies of human and rat colon[6, 7]. However, subtle structural changes including mucin depletion, epithelial cell loss and inflammatory cell infiltration of the mucosa have been reported elsewhere.
Cell proliferation is a commonly used end-point in studies of the effects of exogenous and genetic factors on colonic mucosal function and cancer risk. However, data on the impact of bowel preparation agents on cell proliferation is sparse. A 136% increase in colonocyte Ki-67 labelling index has been reported in patients prepared with NaP, when compared to the same patients, unprepared. Sodium picosulfate was found in an animal study to have no effect on colonocyte proliferation, whilst another detected increased proliferation in response to bisocodyl and sennosides, laxatives with a similar action.
To date, there are no published studies examining or comparing the direct effects of sodium picosulfate and PEG on colonocyte proliferation. This study aims to compare the effects of these two commonly used bowel preparative agents on immunohistochemical and whole-mount derived indices of cell proliferation.
Ethical approval and patient groups
Patients attending endoscopy clinics at the Northern General Hospital, Sheffield for an initial colonoscopy were recruited to the study. Patients were all male, over 40 and had normal bowel health. Smokers and diabetics were excluded. Patients prepared for endoscopy with Klean-Prep (n = 4) or Picolax (n = 3) were invited to return four weeks later for sigmoidoscopy without bowel preparation. Two biopsies were taken at the recto-sigmoid junction. This study was approved by the North Sheffield Research Ethics Committee (Reference number: 06/Q2308/93). Informed consent was obtained from all patients.
Measurement of crypt cell proliferation
The range of markers currently utilised for the assessment of colonocyte proliferation is wide, and may in part account for the variability seen between studies. In this study we employed two recognised immunohistochemical markers of cell proliferation, Ki-67 and pHH3. Ki-67 is expressed throughout the cell cycle, whilst pHH3 (phosphorylated histone H3) is detectable in increasing quantity during the progression from from interphase to prophase. This correlates with a progression from granular to diffuse immunohistochemical staining patterns. Counts for both staining patterns were recorded. Where possible, an additional biopsy from each site was taken for whole-crypt mitotic count, assessed using the microdissection method described by Goodlad, et. al.
Biopsies were fixed for 24 hours in formalin before paraffin embedding and cutting of serial 4-micron sections at 40-micron intervals. Endogenous peroxidise activity was blocked with 2% hydrogen peroxide. Heat-induced eiptope retrieval (HIER) was performed using a sodium citrate buffer (pH 6.0) for Ki-67 and EDTA (pH 8.0) for pHH3. Non-specific immunoglobulin binding sites were blocked with normal horse serum. Slides were incubated for 1 hour with primary antibodies to Ki-67 (Vector Laboratories VP-K 452) and pHH3 (Upstate 06–570) at 1:100 and 1:200, respectively. Staining was visualised with the Vectastain Universal Elite kit and DAB peroxidise substrate (Vector Laboratories). Sections were counter-stained with Gill's haematoxylin.
A maximum of 10 well-orientated hemi-crypts per biopsy, showing the entire length of the crypt wall from the base abutting the muscularis mucosa through to the junction with the surface epithelium, were included. Images were captured at 20× magnification with a Nikon D5-M camera at 2560 × 1920 resolution, stored without compression and analysed using Nikon NIS-Elements D (v 2.30) software. All cell counts and measurements were made by one observer blind to the status of the biopsy. A subset of scores was confirmed by a second independent observer.
The number of cells showing positive nuclear staining for each antigen was recorded as a fraction of the total cell count per hemi-crypt (labelling index:LI). For pHH3, the LIs for granular and diffuse staining were recorded separately. Crypt lengths for up to five crypts per biopsy were determined.
Whole mount analysis
Whole biopsies were fixed in Carnoy's fluid, then stored in 70% ethanol. Rehydration through 50% and 25% alcohols and PBS was followed by hydrolysis in 5 M NaOH at room temperature. After staining with Schiff's reagent for 90 minutes, the biopsies were transferred to 45% acetic acid for dissection. Small groups of crypts were isolated from surrounding tissue under a dissecting microscope, then transferred to slides and squashed with thumb pressure under a cover-slip with aqueous mountant. Mitoses were counted at ×40 in up to ten whole crypts per biopsy, through the full crypt depth. Nuclei in all phases of mitosis were counted and expressed as the number of mitoses per crypt.
Statistical analysis was carried out with SPSS (version 11.0). The distribution of values for each parameter was tested for normality using the Kolmorogov-Smirnov test. Indices for paired biopsies (i.e those from the same patient, with and without preparation) were compared using the paired Student t-test. One-way ANOVA was used to test for the equality of the means for each parameter between each group (no preparation, Klean-Prep and Picolax), and the unpaired t-test was used to test for differences between biopsies taken after Klean-prep and those taken after Picolax.
Results and discussion
Immunohistochemical methods for the assessment of cell proliferation in small biopsies suffer from a number of potential disadvantages. Firstly, it can be difficult to obtain high yields of assessable crypts in histological sections. Secondly, there is concern over the impact of the so called "denominator effect" on the LI. Counting mitotic figures in whole-mount preparations avoids these issues, but does suffer the disadvantage that a second biopsy must be obtained if conventional histolological examination (or additional immunohistochemical staining, e.g. for apoptosis) is required. We compared the statistical reliability of both approaches using the Cronbach's alpha statistic -a measure of between and within-case variability, ranging from 0 to 1 with increasing reliability. The scores were 0.9476 and 0.9164 for Ki-67 and whole mount mitotic counts, respectively, indicating that robust measurements can be obtained without exhaustive sampling of crypts. Moreover, scores from both methods correlated well (Pearson correlation coefficient 0.655, p = 0.008). There is also concern that individual antibody targets may not display expression that is truly restricted to proliferating cells, and therefore give potentially spurious results. It is reassuring that the immunohistochemical markers used in this study both showed similar results.
This observation may be relevant to the interpretation of proliferation data in several recently published studies. In one study demonstrating no significant difference in Ki-67 or whole crypt mitoses between patients with Hereditary non-polyposis colorectal cancer and normal subjects, the authors concluded that crypt cell proliferation is not a suitable discriminative marker for this disease. All patients had been administered Picolax and, as in our study, had Ki-67 LIs in the range 0.3 to 0.4. A study on the effect of pre-biotic carbohydrates similarly showed no difference in Ki-67 LI between subjects and controls, reporting indices between 0.3 and 0.4. Again, all subjects received Picolax. Our evidence suggests that any marginal change in LI in response to disease or intervention in these studies may have been masked by the proliferative effects of Picolax. Equally, data from studies based on subjects prepared with PEG should be interpreted cautiously. No association was found between the PCNA proliferative index (PI) and the likelihood of developing adenoma in one prospective study; the majority of these patients were prepared with PEG. It is possible that PEG suppressed colonocyte proliferation in a group of patients that might be expected to have a higher than normal PI.
Crypt length and cellularity
No significant differences were seen by t-test analysis between pairs for either Klean-Prep or Picolax (p = 0.766 and 0.183, respectively), or between groups by one-way ANOVA (p = 0.437). Similarly, there was no significant difference in crypt length between pairs (p = 0.209 for Klean-prep, p = 0.827 for Picolax), or between groups by one-way ANOVA (p = 0.0786) (data not shown). The cellular homeostasis observed despite increased proliferation could be attributed to two factors. Firstly, the interval between bowel preparation and biopsy (typically 12 hours) may have been insufficient for any cells entering cell division to complete the cycle. Secondly, the observed homeostasis may be attributable to increased apoptosis. Our assessment of apoptotic indices recorded very low rates of background apoptosis in all samples, and showed no alteration in response to bowel preparation (data not shown).
Limitations of study
A randomisation bias on clinical grounds cannot be ruled out in the allocation of patients to Klean-Prep or Picolax preparation; this, along with the small sample size, may in part account for the lack of statistical significance seen between prepared patients and unprepared controls. Similarly, whilst patients prepared with Klean-Prep or Picolax fasted prior to colonoscopy, control patients did not, and potential confounding influences of luminal nutrition and luminal workload on proliferation indices should be noted. However, our analyses, and the central finding of this study, show an opposing direction of change between Klean-Prep and Picolax that is consistent for all proliferation measures, and cannot be a feature of starvation. Although the small number of cases and the single sampling site inevitably means that the results should be interpreted with caution, this pilot study has informed our choice of procedural homogeneity for a separate, larger study requiring repeat endoscopies.
This study demonstrates that Picolax and Klean-Prep have significantly different effects on crypt cell proliferation. Suppression or elevation of proliferation parameters by bowel preparation may mask any effect due to an intervention or disease.
These data underscore the importance of ensuring that all patients participating in studies in which crypt proliferation is an outcome measure are treated with identical bowel preparation. Bowel preparations used in such studies should be reported, and the data interpreted with caution.
This study was supported by a Food Standards Agency award (N12017). We acknowledge the assistance of H. Norwood with recruiting.
- Nelson DB, Barkun AN, Block KP, Burdick JS, Ginsberg GG, Greenwald DA, Kelsey PB, Nakao NL, Slivka A, Smith P, et al: Technology Status Evaluation report. Colonoscopy preparations. May 2001. Gastrointestinal endoscopy. 2001, 54 (6): 829-832.View ArticlePubMed
- Lieberman DA, Ghormley J, Flora K: Effect of oral sodium phosphate colon preparation on serum electrolytes in patients with normal serum creatinine. Gastrointestinal endoscopy. 1996, 43 (5): 467-469. 10.1016/S0016-5107(96)70287-0.View ArticlePubMed
- Fordtran JS, Santa Ana CA, Cleveland MvB: A low-sodium solution for gastrointestinal lavage. Gastroenterology. 1990, 98 (1): 11-16.PubMed
- Kastenberg D, Chasen R, Choudhary C, Riff D, Steinberg S, Weiss E, Wruble L: Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: two identically designed, randomized, controlled, parallel group, multicenter phase III trials. Gastrointestinal endoscopy. 2001, 54 (6): 705-713. 10.1067/mge.2001.119733.View ArticlePubMed
- Bucher P, Gervaz P, Egger JF, Soravia C, Morel P: Morphologic alterations associated with mechanical bowel preparation before elective colorectal surgery: a randomized trial. Diseases of the colon and rectum. 2006, 49 (1): 109-112. 10.1007/s10350-005-0215-5.View ArticlePubMed
- Erdogan B, Isiksoy S, Dundar E, Pasaoglu O, Bal C: The effects of sodium phosphate and polyethylene glycol-electrolyte bowel preparation solutions on 2,4,6-trinitrobenzenesulfonic acid-induced colitis in the rat. Exp Toxicol Pathol. 2003, 55 (2–3): 213-220. 10.1078/0940-2993-00318.View ArticlePubMed
- Fa-Si-Oen PR, Penninckx F: The effect of mechanical bowel preparation on human colonic tissue in elective open colon surgery. Diseases of the colon and rectum. 2004, 47 (6): 948-949. 10.1007/s10350-004-0515-1.View ArticlePubMed
- Zwas FR, Cirillo NW, el-Serag HB, Eisen RN: Colonic mucosal abnormalities associated with oral sodium phosphate solution. Gastrointestinal endoscopy. 1996, 43 (5): 463-466. 10.1016/S0016-5107(96)70286-9.View ArticlePubMed
- Driman DK, Preiksaitis HG: Colorectal inflammation and increased cell proliferation associated with oral sodium phosphate bowel preparation solution. Human pathology. 1998, 29 (9): 972-978. 10.1016/S0046-8177(98)90203-9.View ArticlePubMed
- Yang K, Fan K, Mengs U, Lipkin M: Effects of sennosides and nonanthranoid laxatives on cytochemistry of epithelial cells in rat colon. Pharmacology. 1993, 47 (Suppl 1): 196-204. 10.1159/000139872.View ArticlePubMed
- Geboes K, Nijs G, Mengs U, Geboes KP, Van Damme A, de Witte P: Effects of 'contact laxatives' on intestinal and colonic epithelial cell proliferation. Pharmacology. 1993, 47 (Suppl 1): 187-195. 10.1159/000139858.View ArticlePubMed
- Toyoda K, Nishikawa A, Furukawa F, Kawanishi T, Hayashi Y, Takahashi M: Cell proliferation induced by laxatives and related compounds in the rat intestine. Cancer Lett. 1994, 83 (1–2): 43-49. 10.1016/0304-3835(94)90297-6.View ArticlePubMed
- Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP, Allis CD: Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997, 106 (6): 348-360. 10.1007/s004120050256.View ArticlePubMed
- Goodlad RA, Levi S, Lee CY, Mandir N, Hodgson H, Wright NA: Morphometry and cell proliferation in endoscopic biopsies: evaluation of a technique. Gastroenterology. 1991, 101 (5): 1235-1241.PubMed
- Green SE, Chapman P, Burn J, Burt AD, Bennett M, Appleton DR, Varma JS, Mathers JC: Colonic epithelial cell proliferation in hereditary non-polyposis colorectal cancer. Gut. 1998, 43 (1): 85-92.PubMed CentralView ArticlePubMed
- Langlands SJ, Hopkins MJ, Coleman N, Cummings JH: Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut. 2004, 53 (11): 1610-1616. 10.1136/gut.2003.037580.PubMed CentralView ArticlePubMed
- Sandler RS, Baron JA, Tosteson TD, Mandel JS, Haile RW: Rectal mucosal proliferation and risk of colorectal adenomas: results from a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2000, 9 (7): 653-656.PubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/8/54/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.